Chinese R&D Center Planned By Novartis Oncology In Shanghai
This article was originally published in PharmAsia News
Executive Summary
China is the focus of a new effort by Novartis Oncology to expand research-and-development work abroadYou may also be interested in...
Industry Delighted By ‘Fixed’ USMCA
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
NeuClone’s Trastuzumab Trial Succeeds
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.
Need a specific report? 1000+ reports available
Buy Reports